SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, hormone-receptor positive HER2 negative advanced breast cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary) ; Fulvestrant (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms SEQUEL-Breast

Most Recent Events

10 Dec 2022 Till June 27, 2023 (n=3) patients were enrolled, as per trial design presented at the 45th Annual San Antonio Breast Cancer Symposium.
10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium.
01 Jun 2022 Planned initiation date changed from 1 May 2022 to 2 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight